Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.50
SQNM's Cash to Debt is ranked lower than
87% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. SQNM: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
SQNM' s Cash to Debt Range Over the Past 10 Years
Min: 0.41  Med: 12.34 Max: No Debt
Current: 0.5
Equity to Asset -0.48
SQNM's Equity to Asset is ranked lower than
96% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SQNM: -0.48 )
Ranked among companies with meaningful Equity to Asset only.
SQNM' s Equity to Asset Range Over the Past 10 Years
Min: -0.48  Med: 0.68 Max: 0.96
Current: -0.48
-0.48
0.96
F-Score: 2
Z-Score: -12.82
M-Score: -3.56
WACC vs ROIC
4.50%
-146.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -30.25
SQNM's Operating margin (%) is ranked higher than
60% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. SQNM: -30.25 )
Ranked among companies with meaningful Operating margin (%) only.
SQNM' s Operating margin (%) Range Over the Past 10 Years
Min: -255  Med: -79.03 Max: -6.14
Current: -30.25
-255
-6.14
Net-margin (%) -37.33
SQNM's Net-margin (%) is ranked higher than
57% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. SQNM: -37.33 )
Ranked among companies with meaningful Net-margin (%) only.
SQNM' s Net-margin (%) Range Over the Past 10 Years
Min: -254.63  Med: -79.89 Max: 0.67
Current: -37.33
-254.63
0.67
ROA (%) -34.74
SQNM's ROA (%) is ranked lower than
57% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. SQNM: -34.74 )
Ranked among companies with meaningful ROA (%) only.
SQNM' s ROA (%) Range Over the Past 10 Years
Min: -92.63  Med: -50.90 Max: 0.66
Current: -34.74
-92.63
0.66
ROC (Joel Greenblatt) (%) -323.58
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SQNM: -323.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SQNM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -895.1  Med: -369.48 Max: -62.87
Current: -323.58
-895.1
-62.87
Revenue Growth (3Y)(%) 11.20
SQNM's Revenue Growth (3Y)(%) is ranked higher than
63% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SQNM: 11.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SQNM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.7  Med: -14.00 Max: 49.8
Current: 11.2
-20.7
49.8
EPS Growth (3Y)(%) -48.60
SQNM's EPS Growth (3Y)(%) is ranked lower than
90% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. SQNM: -48.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SQNM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.3  Med: -27.10 Max: 43.9
Current: -48.6
-59.3
43.9
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

SQNM Guru Trades in Q1 2015

Jim Simons 89,700 sh (+161.97%)
» More
Q2 2015

SQNM Guru Trades in Q2 2015

Jim Simons 388,400 sh (+333.00%)
» More
Q3 2015

SQNM Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q1 2016

SQNM Guru Trades in Q1 2016

Jim Simons 86,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RDHL, NAS:ARQL, NAS:GLYC, NAS:AXSM, NAS:STML, NAS:KMDA, OTCPK:SLNCF, NAS:CARA, NAS:OVAS, NAS:EARS, OTCPK:CYDY, NAS:ECYT, NAS:ANTH, OTCPK:CLVLF, NAS:VCYT, NAS:OCUL, NAS:NYMX, NAS:CDTX, NAS:ARGS, AMEX:AST » details
Traded in other countries:QNMA.Germany,
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Top Ranked Articles about Sequenom Inc

Weekly CFO Buys Highlight Recent insider buys from company CFOs
According to GuruFocus Insider Data, the recent CFO buys were: Orion Energy Systems Inc. (NASDAQ:OESX), Sequenom Inc. (NASDAQ:SQNM) and Energy Recovery Inc. (NASDAQ:ERII). Read more...
Sequenom Officer Acquires 30,000 Shares CEO, president invests in life science company
Dirk van den Boom (Insider Trades), CEO and president of Sequenom Inc. (SQNM), acquired 30,000 shares in the company on May 6. The average price per share was $1.13 for a total transaction of $33,900. Read more...
Weekly CFO Buys Highlight: Infinera, Sequenom, Pandora Media Recent insider buys from company CFOs
According to GuruFocus insider data, the recent CFO buys were Infinera Corp. (NASDAQ:INFN), Sequenom Inc. (NASDAQ:SQNM) and Pandora Media Inc. (NYSE:P). Read more...

Ratios

vs
industry
vs
history
P/S 0.94
SQNM's P/S is ranked higher than
92% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. SQNM: 0.94 )
Ranked among companies with meaningful P/S only.
SQNM' s P/S Range Over the Past 10 Years
Min: 0.94  Med: 5.39 Max: 28.11
Current: 0.94
0.94
28.11
Current Ratio 3.85
SQNM's Current Ratio is ranked lower than
56% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SQNM: 3.85 )
Ranked among companies with meaningful Current Ratio only.
SQNM' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 3.85 Max: 26.12
Current: 3.85
1.15
26.12
Quick Ratio 3.71
SQNM's Quick Ratio is ranked lower than
54% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SQNM: 3.71 )
Ranked among companies with meaningful Quick Ratio only.
SQNM' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 3.56 Max: 26.03
Current: 3.71
0.94
26.03
Days Inventory 20.70
SQNM's Days Inventory is ranked higher than
88% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. SQNM: 20.70 )
Ranked among companies with meaningful Days Inventory only.
SQNM' s Days Inventory Range Over the Past 10 Years
Min: 24.35  Med: 85.76 Max: 229.88
Current: 20.7
24.35
229.88
Days Sales Outstanding 21.49
SQNM's Days Sales Outstanding is ranked higher than
81% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. SQNM: 21.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
SQNM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.73  Med: 49.34 Max: 97.54
Current: 21.49
5.73
97.54
Days Payable 40.09
SQNM's Days Payable is ranked lower than
64% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. SQNM: 40.09 )
Ranked among companies with meaningful Days Payable only.
SQNM' s Days Payable Range Over the Past 10 Years
Min: 26.62  Med: 115.72 Max: 169.77
Current: 40.09
26.62
169.77

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.18
SQNM's Price/Median PS Value is ranked higher than
92% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. SQNM: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
SQNM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.91 Max: 22.54
Current: 0.18
0.21
22.54
Earnings Yield (Greenblatt) (%) -19.94
SQNM's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. SQNM: -19.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SQNM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.94  Med: 6.00 Max: 6690.1
Current: -19.94
-19.94
6690.1

More Statistics

Revenue (TTM) (Mil) $118.0
EPS (TTM) $ -0.37
Beta0.31
Short Percentage of Float15.10%
52-Week Range $0.92 - 3.31
Shares Outstanding (Mil)119.22

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 122 125
EPS ($) -0.29 -0.31
EPS w/o NRI ($) -0.29 -0.31
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlights Jun 21 2016 
Weekly CFO Buys Highlight Jun 13 2016 
Sequenom Officer Acquires 30,000 Shares May 10 2016 
Weekly CFO Buys Highlight: Infinera, Sequenom, Pandora Media May 08 2016 
Insiders Are Selling Dave & Buster's Entertainment and Buying Twinlab Oct 09 2015 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 

More From Other Websites
The Supreme Court Of The United States Denies Sequenom's Petition Requesting Review Of Decision On... Jun 27 2016
10:35 am Sequenom confirms negative Supreme Court ruling Jun 27 2016
The Supreme Court Of The United States Denies Sequenom's Petition Requesting Review Of Decision On... Jun 27 2016
U.S. Supreme Court refuses to review prenatal test patent dispute Jun 27 2016
U.S. Supreme Court weighs review of canceled patent on prenatal test Jun 23 2016
U.S. Supreme Court weighs review of canceled patent on prenatal test Jun 23 2016
Weekly CFO Buys Highlights Jun 21 2016
SEQUENOM INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Jun 17 2016
Weekly CFO Buys Highlight Jun 13 2016
Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment Jun 09 2016
Ultra Petroleum Tops Dollar-Stock Gainers on Natural-Gas Spike Jun 09 2016
Sequenom Files Patent Infringement Lawsuit in Australia Jun 07 2016
Sequenom Files Patent Infringement Lawsuit in Australia Jun 07 2016
ETF’s with exposure to Sequenom, Inc. : June 6, 2016 Jun 06 2016
Sequenom to Present at Jefferies Global Healthcare Conference Jun 02 2016
Sequenom to Present at Jefferies Global Healthcare Conference Jun 02 2016
ETF’s with exposure to Sequenom, Inc. : May 16, 2016 May 16 2016
SEQUENOM INC Financials May 13 2016
Sequenom, Inc. :SQNM-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Sequenom Officer Acquires ‘…,……… Shares May 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)